08:41 AM EDT, 03/30/2026 (MT Newswires) -- Aurinia Pharmaceuticals ( AUPH ) said Monday it has entered into a definitive agreement to acquire Kezar Life Sciences ( KZR ) for $6.955 in cash and one non-transferable contingent value right per Kezar share.

Each contingent value right represents the right to receive potential payments linked to zetomipzomib's clinical development or disposition, all of Kezar's closing net cash in excess of $50 million, as well as certain proceeds from Kezar's collaboration with Everest Medicines and Kezar's sale of its Sec61-based discovery and development program to Enodia Therapeutics, Aurinia said.

Under the agreement, Aurinia said it will begin a tender offer to acquire all Kezar outstanding shares through its subsidiary Aurinia Pharma US and its merger subsidiary Aurinia Merger Sub by April 13.

The transaction is expected to close in Q2, the company said.